CCA
RYTM icon

Column Capital Advisors’s Rhythm Pharmaceuticals RYTM Stock Holding History

Column Capital Advisors’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-149
Closed -$3K – 784
2019
Q4 		$3K Buy
+149
New +$3.31K ﹤0.01% 588

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Column Capital Advisors's RYTM Position: Q1 2020 in Review

Column Capital Advisors sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2020, closing a stake of 149 shares — an estimated $3K sold.

Column Capital Advisors first reported a position in RYTM in Q4 2019 and held it in 1 quarter. The position peaked at $3K in Q4 2019. 80 funds tracked by Wall St. Rank hold RYTM as of Q1 2020.

  • Column Capital Advisors reported no remaining Rhythm Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Column Capital Advisors sold 149 Rhythm Pharmaceuticals shares in Q1 2020, an estimated $3K.
  • Column Capital Advisors first reported a position in Rhythm Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • Column Capital Advisors's Rhythm Pharmaceuticals position peaked at $3K in Q4 2019.
  • 80 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2020.

Based on Column Capital Advisors's 13F filing for Q1 2020, filed 11 May 2020.